Trial Profile
Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) Added to Fludarabine, Bendamustine and Rituximab and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 24 Jul 2023
Price :
$35
*
At a glance
- Drugs Inotuzumab ozogamicin (Primary) ; Antithymocyte globulin; Bendamustine; Filgrastim; Fludarabine; Methotrexate; Rituximab; Tacrolimus; Tacrolimus
- Indications B-cell leukaemia; B-cell lymphoma
- Focus Adverse reactions
- 20 Jul 2023 Status changed from active, no longer recruiting to completed.
- 30 Jun 2023 Planned End Date changed from 30 Jun 2023 to 30 Sep 2023.
- 30 May 2023 Planned primary completion date changed from 30 Jun 2023 to 30 Sep 2023.